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Objective: To assess the effects of maintenance therapy with aripiprazole once-monthly 400 mg on personal and
social functioning.
Methods: Data were analyzed from 2 randomized, double-blind trials of patients with schizophrenia requiring
chronic antipsychotic treatment. One study was a 52-week trial of aripiprazole once-monthly 400 mg versus
placebo; the other was a 38-week trial of aripiprazole once-monthly 400 mg, oral aripiprazole (10–30 mg
daily), and aripiprazole once-monthly 50 mg (subtherapeutic dose to test assay sensitivity). Functioning was
assessed using the Personal and Social Performance (PSP) scale, comprising 4 domain subscales.
Results: In the 52-week study, 403 patients stabilized on aripiprazole once-monthly 400mgwere randomized to
receive aripiprazole once-monthly 400 mg (n= 269) or placebo (n= 134). In the 38-week study, 662 patients
stabilized on oral aripiprazole were randomized to receive aripiprazole once-monthly 400 mg (n = 265), oral
aripiprazole (n = 266), or aripiprazole once-monthly 50 mg (subtherapeutic dose; n = 131). In the 52-week
study, mean changes from baseline were signiﬁcantly worsened with placebo compared with aripiprazole
once-monthly 400 mg for PSP total score (P b 0.001) and domain scores for Personal and Social Relationships
(P b 0.001), Self-Care (P b 0.01), and Disturbing and Aggressive Behavior (P b 0.0001). In the 38-week study,
mean changes from baseline were signiﬁcantly worsened with aripiprazole once-monthly 50 mg compared
with aripiprazole once-monthly 400 mg for PSP total score (P b 0.05) and the Personal and Social Relationships
domain score (P b 0.05).
Conclusion: Patient functioning, assessed using the PSP scale, was maintained in stabilized patients treated with
aripiprazole once-monthly in 2 pivotal relapse studies.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Schizophrenia is a severe, chronic, and formost patients, progressive
disease, and a fundamental goal of long-termmaintenance therapy is to
optimize patient functioning and quality of life (Hasan et al., 2013). A
key component of maintaining patient functionality is relapse prevention
(Harvey et al., 2013), whichmay also reduce the associated socioeconomiciatry, Department of Psychiatry
strasse 35, A-6020 Innsbruck,
67.
.W. Fleischhacker).
. This is an open access article underburden of the disease (Awad and Voruganti, 2008; Hong et al., 2009; Karve
et al., 2012).Recent international treatment guidelines recommend con-
tinuous antipsychotic treatment for relapse prevention (Buchanan
et al., 2010; Kreyenbuhl et al., 2010; Hasan et al., 2013). Long-acting
injectable (LAI) formulations of antipsychotics are valuable treatment
alternatives to oral formulations for facilitating relapse prevention
because of their potential to facilitate adherence monitoring (Hasan
et al., 2013; Rauch and Fleischhacker, 2013).
Aripiprazole once-monthly, an extended-release injectable suspen-
sion for intramuscular use, is theﬁrst dopamine partial agonist available
as an LAI. Aripiprazole once-monthly is approved for the treatment of
schizophrenia. In a 52-week, randomized, double-blind trial, aripiprazolethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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delayed time to impending relapse compared with placebo (Kane et al.,
2012). In a subsequent 38-week, randomized, double-blind trial with
rate of impending relapse as the primary endpoint, aripiprazole once-
monthly 400 mg (with an option to reduce to 300 mg) was noninferior
to oral aripiprazole 10 to 30mg andmore effective than a subtherapeutic
50-mg dose of aripiprazole once-monthly used to test assay sensitivity
(Fleischhacker et al., 2014). The safety and tolerability proﬁle of
aripiprazole once-monthly 400 mg was similar in both studies (Kane
et al., 2012; Fleischhacker et al., 2014) and consistentwith that reported
for oral aripiprazole in previous registrational maintenance studies
(Kasper et al., 2003; Pigott et al., 2003).
Although patients in both aripiprazole once-monthly 400mg studies
also demonstrated symptomatic improvement (Kane et al., 2012;
Fleischhacker et al., 2014), symptomatic improvements are not always
associatedwith functional improvements in patientswith schizophrenia
(Tandon et al., 2010; Harvey et al., 2012; Karow et al., 2012;Wunderink
et al., 2013). To further characterize the efﬁcacy of aripiprazole once-
monthly 400 mg for the treatment of schizophrenia, we assessed, and
are reporting for the ﬁrst time, personal and social functioning in
the 52-week (Kane et al., 2012) and 38-week studies (Fleischhacker
et al., 2014) using the Personal and Social Performance (PSP) scale
(Morosini et al., 2000). Furthermore, we evaluated both total and PSP
domain scores.
2. Methods
2.1. Patients and study designs
Data were analyzed from a 52-week, multicenter, randomized,
double-blind, placebo-controlled trial (ClinicalTrials.gov Identiﬁer,
NCT00705783) (Kane et al., 2012) and a 38-week,multicenter, random-
ized, double-blind, active-controlled trial (ClinicalTrials.gov Identiﬁer,
NCT00706654) (Fleischhacker et al., 2014). The trials were conducted
in accordance with the Declaration of Helsinki and Good Clinical Prac-
tice, the protocols were reviewed by the institutional review board
at each center, any potential adverse events were fully explained to
patients, and all patients provided written informed consent.
Study designs were previously described in detail (Kane et al., 2012;
Fleischhacker et al., 2014). In brief, the 52-week study consisted of a
screening phase, an oral conversion phase (4–6 weeks), an oral stabili-
zation phase (4–12 weeks), an aripiprazole once-monthly stabilization
phase (12–36 weeks), and a double-blind, placebo-controlled phase
(52 weeks). During the aripiprazole once-monthly stabilization phase,
patients were permitted, if required based on tolerability, a single
decrease to 300 mg and a single return to 400 mg. Patients who met
stability criteria were randomized to double-blind treatment (2:1)
with aripiprazole once-monthly 400 mg or placebo. The primary efﬁca-
cy endpoint was the time to impending relapse. Based on a prespeciﬁed
interim analysis (performed after 64 events), an independent data
monitoring committee concluded that the primary endpoint had been
met, with no safety issues of particular concern, resulting in early termi-
nation of the 52-week study to avoid continued exposure to placebo.
The 38-week study comprised a screening phase, an oral conversion
phase (4–6 weeks), an oral stabilization phase (8–28 weeks), and a
double-blind maintenance phase (38 weeks). During the double-blind
maintenance phase, patients who met stability criteria were randomly
assigned (2:2:1) to treatment with aripiprazole once-monthly 400 mg,
oral aripiprazole 10 to 30 mg daily (based on stabilization dose), or
aripiprazole once-monthly 50 mg (low dose included to test assay sen-
sitivity for the noninferiority design). Patients initiated on aripiprazole
once-monthly 400 mg or 50 mg were allowed a one-time dose reduc-
tion to 300 mg or 25 mg, respectively, as well as a one-time return
to the original dose. The primary efﬁcacy endpoint was the estimated
proportion of patients experiencing impending relapse by the end of
26 weeks from randomization to the double-blind maintenance phase.Patient inclusion and exclusion criteria were previously described in
detail (Kane et al., 2012; Fleischhacker et al., 2014). In brief, eligible
patients were 18 to 60 years of age with a Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR™)
diagnosis of schizophrenia for ≥3 years before screening who were
considered by the investigators to require chronic antipsychotic
treatment.
2.2. Assessment of personal and social functioning
Personal and social functioning were measured using the 100-point
PSP scale, a validated clinician-rated scale that measures personal and
social functioning across 4 domains: (1) Socially Useful Activities, In-
cluding Work and Study, (2) Personal and Social Relationships,
(3) Self-Care, and (4) Disturbing and Aggressive Behaviors (Morosini
et al., 2000). Impairment in each domain was rated on a 6-point scale
(0 = absent, 1 = mild, 2 = manifest, 3 = marked, 4 = severe, and
5 = very severe). PSP total score ratings were converted to a 0- to
100-point total score (71–100, mild functional difﬁculty; 31–70, vary-
ing degrees of disability; 1–30, minimal functioning needing intense
support and/or supervision) using algorithms to identify the
appropriate 10-point interval within the 100-point range and using
the rater's judgment to determine the total score within the 10-point
interval. To provide additional insight into the domains of PSP, we
report actual baseline mean domain scores and mean change scores
based on actual investigator ratings, where decreasing scores indicate
improved function.
2.3. Statistical analyses
In the 52-week study, PSP total score was assessed at baseline and
week 12/last visit of the oral stabilization phase, week 36/last visit of
the aripiprazole once-monthly stabilization phase, and week 52/last
visit of the double-blind, placebo-controlled phase. The value at the
end of the aripiprazole once-monthly stabilization phase, on the day
of randomization before the ﬁrst dose of double-blind medication,
served as the baseline for the double-blind, placebo-controlled phase.
Change from baseline to week 52/last visit in PSP total score during
the double-blind, placebo-controlled phase was analyzed using analysis
of covariance (ANCOVA; last observation carried forward [LOCF]), with
treatment as a factor and baseline value as a covariate.
In the 38-week study, PSP total score was assessed at baseline and
week 28/last visit of the oral stabilization phase, and week 38/last visit
of the double-blind maintenance phase. Change from baseline in PSP
total score during the double-blind maintenance phase was analyzed
using ANCOVA (LOCF), with treatment as a factor and baseline value
as a covariate.
As with PSP total score, changes from baseline in PSP domain scores
during the double-blind phases of both studies were analyzed post-hoc
using ANCOVA (LOCF), with treatment as a factor and baseline value as
a covariate.
Additional post-hoc subgroup analyses evaluated change from base-
line in PSP total and domain scores during the double-blind phases
of both studies in the subgroup of patients with impending relapse, as
deﬁned in the primary publications (Kane et al., 2012; Fleischhacker
et al., 2014). These analyses used ANCOVA (LOCF), with treatment as a
factor and baseline value as a covariate.
3. Results
3.1. Patient disposition and characteristics
Patient disposition and demographics were detailed in the primary
study publications (Kane et al., 2012; Fleischhacker et al., 2014). In the
52-week study, 1025 patients were screened, 843 were enrolled, and
403 entered the double-blind, placebo-controlled phase (aripiprazole
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terminated early, 51 (8.9%) patients received at least 12 months
(13 injections) of aripiprazole once-monthly 400 mg treatment during
the aripiprazole once-monthly 400 mg stabilization and double-blind,
placebo-controlled phases. Baseline demographic and disease charac-
teristics were similar between groups. Mean (SD) age was 40.6 (10.8)
years. The majority of patients were men (59.8%) and white (60.5%).
Mean (SD) age at ﬁrst diagnosis was 26.0 (8.5) years.
In the 38-week study, 1118 patients were screened, 937 were en-
rolled, 662 were randomized to double-blind treatment (aripiprazole
once-monthly 400mg, n=265; oral aripiprazole, n=266; aripiprazole
once-monthly 50 mg, n = 131), and 435 (65.7%) completed 38 weeks
of treatment. Baseline demographic and disease characteristics were
similar between treatment groups. Mean (SD) age was 41.2 (10.4)
years, 61.3% of patients were men, and 58.5% were white. Mean (SD)
age at ﬁrst diagnosis was 27.3 (9.0).
3.2. Personal and social functioning
3.2.1. PSP total score
In the 52-week study,mean (SD) PSP total scorewas62.7 (14.1) (i.e.,
varying degrees of disability) at the beginning of the oral stabilization
phase. Mean PSP total scores increased from baseline to last visit of
the oral stabilization phase (indicative of improvement) and from base-
line to last visit of the aripiprazole once-monthly stabilization phase.
During the double-blind, placebo-controlled phase, change from base-
line in PSP total scoreswas signiﬁcantly greater atweek 52with placebo
compared with aripiprazole once-monthly 400 mg, indicating greater
functional deterioration with placebo (P b 0.001; Fig. 1A).
In the 38-week study, mean (SD) PSP total score was 63.3 (12.6) at
the beginning of the oral stabilization phase and was increased at the
ﬁnal visit. During the double-blind maintenance phase, PSP total scores
remained fairly stable in the aripiprazole once-monthly 400mgandoral
aripiprazole groups but decreased in the aripiprazole once-monthly
50 mg group; there was no difference between aripiprazole once-
monthly 400 mg and oral aripiprazole (Fig. 1B). Mean change from
baseline in PSP total score at week 38 was signiﬁcantly greater with
aripiprazole once-monthly 50 mg compared with aripiprazole once-
monthly 400 mg and oral aripiprazole, indicating greater functional
deterioration with aripiprazole once-monthly 50 mg (P b 0.05; Fig. 1B).
3.2.2. PSP domain scores
Changes from baseline in actual mean PSP domain scores during the
double-blind, placebo-controlled phase of the 52-week study are plot-
ted in Fig. 2A. Across groups, mean PSP domain scores at randomization
were all less than 2, indicating no greater than mild impairment. PSP
domain scores increased slightly (≤0.5 points on the 6-point domain
score scale) in both groups during the double-blind, placebo-controlled
phase, indicative of worsening, but remained below 2. Mean change
from baseline in Socially Useful Activities domain score at week 52
was not signiﬁcantly different between treatment groups, whereas
there was a signiﬁcant difference between placebo and aripiprazole
once-monthly 400 mg for the domains of Personal and Social Relation-
ships, Self-Care, and Disturbing and Aggressive Behaviors (P b 0.001,
P b 0.01, and P b 0.0001, respectively), indicating greater functional de-
terioration with placebo.
Changes from baseline in mean PSP domain scores during the
double-blind maintenance phase of the 38-week study are plotted in
Fig. 2B. Across groups, mean PSP domain scores at week 38 were
all less than 2, indicating no greater than mild impairment. At week
38, mean change from baseline in the Personal and Social Relationships
domain score was signiﬁcantly greater with aripiprazole once-monthly
50 mg compared with aripiprazole once-monthly 400 mg and oral
aripiprazole (P b 0.05), indicating greater deterioration with aripiprazole
once-monthly 50 mg. There was no difference between aripiprazole
once-monthly 400 mg and oral aripiprazole. Signiﬁcant differencesbetween groups were not observed for the other domain scores at
week 38.
3.2.3. PSP scores in patients with impending relapse
In the subgroup of patients with impending relapse in the 52-week
study, the mean (SD) double-blind, placebo-controlled baseline PSP
total score was 65.5 (12.27) with aripiprazole once-monthly 400 mg
(n=27) and 65.1 (11.3) with placebo (n= 49). Themean (SD) change
from baseline in PSP total score at week 52 was −16.0 (14.8) and
−12.9 (10.8), respectively.
In the subgroup of patients with impending relapse in the 38-week
study, the mean (SD) double-blind baseline PSP total score was 62.3
(12.2) with aripiprazole once-monthly 400 mg (n = 22), 63.2 (9.6)
with oral aripiprazole (n = 19), and 64.0 (11.2) with aripiprazole
once-monthly 50 mg (n = 29). The mean (SD) change from baseline
in PSP total score at week 38 was −14.4 (16.7), −11.0 (14.0), and
−9.3 (9.7), respectively.
4. Discussion
These results from 2 long-term, randomized, double-blind trials
demonstrate that patient personal and social functioning, assessed
using the PSP scale, improved during the oral and aripiprazole once-
monthly 400 mg stabilization phases (52-week study) and was main-
tained in stabilized patients randomized to continue treatment with
aripiprazole once-monthly 400 mg, compared with worsening in
those receiving placebo (52-week study) or a subtherapeutic dose of
aripiprazole once-monthly (38-week study). Changes on individual do-
main scores were generally consistent with the PSP total change score,
providing further evidence that patient functioning was maintained in
patients treated with aripiprazole once-monthly 400 mg maintenance
therapy. The individual domain data show what the PSP is measuring
and what aspects of personal and social functioning are improving. In
the 38-week study, there were no signiﬁcant differences between
aripiprazole once-monthly 400 mg and oral aripiprazole on the PSP
total or individual domain scores, as may be expected in a randomized,
controlled trial, where adherence is fostered through regular study
visits.
Our results are generally consistentwith a similarly designed relapse
prevention study for the LAI paliperidone palmitate, in which improve-
ments in functioning were observed in the stabilization phases and
maintained in the double-blind phase for the active treatment group,
with worsening in patients randomized to placebo (Hough et al.,
2010). In comparison, in a study examining switching fromoral antipsy-
chotics to paliperidone palmitate and risperidone LAIs, patient function-
ingwas lower at baseline and showed a greater change from baseline in
the ﬁrst 3 months after the switch (Alphs et al., 2013). It appears that
patient functioning is maintained during long-term relapse prevention
trials in which patients have less severe impairment at baseline. How-
ever, compared with relapse prevention studies, where patients are
stable at randomization, studies in patients with acute exacerbations
of schizophrenia generally show larger effect sizes for PSP scores (Kane
et al., accepted for publication; Sliwa et al., 2011).
The exploratory analysis of PSP scores in patients with impending
relapse showed substantial functional deterioration accompanying
relapse. The importance of symptom control in preserving function in
patients with schizophrenia is established (Haynes et al., 2012; Helldin
et al., 2007). However, there is only partial congruence between symp-
tom control and functional status (Karow et al., 2012; Wunderink et al.,
2013),whichmay be partly related to the sensitivity of functional scales
as well as to disease progression despite use of antipsychotic agents
(Tandon et al., 2010). The impact of antipsychotic treatment on func-
tional status is still not clear (Tandon et al., 2010). With the potential
of LAIs to improve adherence, further studies on the effects of LAIs
on patient function are needed. More information on the temporal
relationship between functional decline and impending relapse
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whether re-emergence of symptoms leads to functional decline) may
help clinicians identify patients at risk of relapse before full relapse.
There are several limitations to the present analyses. Both studies
were designed to evaluate patient relapse, and all patients were
stabilized on oral aripiprazole or aripiprazole once-monthly beforerandomization to double-blind treatment. During all stabilization
phases of both studies, PSP total scores improved. As such, the study
designs may have precluded the ability to observe robust improve-
ments in PSP scores during the double-blind studyphases. Also, patients
weremildly symptomatic at study entry (based on Positive andNegative
SyndromeScale [PANSS] scores),whichmay limit the generalizability of
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in the treatment of acute schizophrenia may help resolve questions
related to the study design limitations.
The geographic heterogeneity of the patients included in the analysis
(i.e., the 52-week and 38-week studies included patients from 12 and
14 countries, respectively) is a strengthwith regard to global applicabil-
ity; however, it is also a limitation because some aspects of personal and
social function may vary based on geoeconomic status. It should also be
noted that the early termination of the 52-week study prevented
patients from receiving aripiprazole once-monthly 400 mg for all
52 weeks of the double-blind period (Kane et al., 2012).
In conclusion, aripiprazole once-monthly 400mgmaintained stabil-
ity in personal and social functioning achieved early in treatment.
Assessed using the PSP scale, functional outcomes deteriorated withplacebo or a subtherapeutic dose of aripiprazole once-monthly (50 mg).
Further studies are warranted to better understand the association
between antipsychotic treatment and functional status, particularly
the relationship between functional decline and relapse.
Role of funding source
Funding for this research was provided by Otsuka Pharmaceutical Development &
Commercialization, Inc. Funding for editorial supportwas provided byOtsuka Pharmaceu-
tical Development & Commercialization, Inc. and H. Lundbeck A/S.
Contributors
W. Wolfgang Fleischhacker, John M. Kane, Robert D. McQuade, Brian R. Johnson,
Pamela P. Perry, William H. Carson, and Raymond Sanchez were involved in conception
and design of the studies. Timothy Peters-Strickland oversaw data analysis and reporting.
Statistical analyseswere conducted by Lan-Feng Tsai. Brian R. Johnson and Pamela P. Perry
420 W.W. Fleischhacker et al. / Schizophrenia Research 159 (2014) 415–420led the execution of the trial. W. Wolfgang Fleischhacker provided patients for the trials.
All authors were involved inmanuscript development, critically reviewed themanuscript
for important intellectual content, and approved the ﬁnal version.
Conﬂicts of interest
W.Wolfgang Fleischhacker has received research grants from Otsuka, Pﬁzer, Janssen,
and Reckitt-Benckiser, as well as consulting honoraria from Lundbeck, Roche, Bristol-
Myers Squibb, Otsuka, Janssen, Pﬁzer, MedAvante, Takeda, Endo, and Vanda. He has re-
ceived speaker honoraria from Lundbeck, Janssen, Otsuka, Roche, and Takeda. He holds
stock fromMedAvante.
Ross A. Baker, Raymond Sanchez, Lan-Feng Tsai, Timothy Peters-Strickland, Pamela P.
Perry, Robert D. McQuade, William H. Carson, and Brian R. Johnson are employees of
Otsuka Pharmaceutical Development & Commercialization, Inc.
Anna Eramo is an employee of Lundbeck LLC.
John M. Kane has received honoraria for lectures and/or consulting from Alkermes,
Amgen, Bristol-Myers Squibb, Cephalon, Eisai, Boehringer Ingelheim, Eli Lilly, Forrest,
Genentech, Intracellular Therapeutics, Janssen, Johnson & Johnson, Lundbeck, Merck,
Novartis, Otsuka, Pﬁzer, Pierre Fabre, Proteus, Reviva, Roche, Sunovion, and Targacept.
He is a shareholder of MedAvante.
Acknowledgments
Editorial support for the preparation of this manuscript was provided by Brett D.
Mahon, PhD, and Jeffrey Coleman, MA, of C4 MedSolutions, LLC (Yardley, PA), a CHC
Group company, with funding from Otsuka Pharmaceutical Development & Commercial-
ization, Inc., and H. Lundbeck A/S. This research was supported by Otsuka Pharmaceutical
Development & Commercialization, Inc., Princeton, NJ, USA.
References
Alphs, L., Bossie, C.A., Sliwa, J.K., Fu, D.J., Ma, Y.W., Hulihan, J., 2013. Paliperidone palmitate
and risperidone long-acting injectable in subjects with schizophrenia recently treated
with oral risperidone or other oral antipsychotics. Neuropsychiatr. Dis. Treat. 9,
341–350.
Awad, A.G., Voruganti, L.N.P., 2008. The burden of schizophrenia on caregivers: a review.
Pharmacoeconomics 26 (2), 149–162.
Buchanan, R.W., Kreyenbuhl, J., Kelly, D.L., Noel, J.M., Boggs, D.L., Fischer, B.A., Himelhoch,
S., Fang, B., Peterson, E., Aquino, P.R., Keller, W., Schizophrenia Patient Outcomes
Research Team, 2010. The 2009 schizophrenia PORT psychopharmacological treat-
ment recommendations and summary statements. Schizophr. Bull. 36 (1), 71–93.
Fleischhacker, W.W., Sanchez, R., Perry, P.P., Jin, N., Peters-Strickland, T., Johnson, B.R.,
Baker, R.A., Eramo, A., McQuade, R.D., Carson, W.H., Walling, D., Kane, J.M., 2014.
Aripiprazole once-monthly for treatment of schizophrenia: a double-blind,
randomised, non-inferiority study. Br. J. Psychiatry 205 (2), 135–144.
Harvey, P.D., Heaton, R.K., Carpenter Jr., W.T., Green, M.F., Gold, J.M., Schoenbaum, M.,
2012. Functional impairment in people with schizophrenia: focus on employability
and eligibility for disability compensation. Schizophr. Res. 140 (1–3), 1–8.
Harvey, P.D., Loewenstein, D.A., Czaja, S.J., 2013. Hospitalization and psychosis: inﬂuences
on the course of cognition and everyday functioning in people with schizophrenia.
Neurobiol. Dis. 53, 18–25.
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W.F., Thibaut, F.,
Moller, H.J., Wfsbp Task Force on Treatment Guidelines for Schizophrenia, 2013.
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biolog-
ical treatment of schizophrenia, part 2: update 2012 on the long-term treatment of
schizophrenia and management of antipsychotic-induced side effects. World J. Biol.
Psychiatry 14 (1), 2–44.Haynes, V.S., Zhu, B., Stauffer, V.L., Kinon, B.J., Stensland, M.D., Xu, L., Ascher-Svanum, H.,
2012. Long-term healthcare costs and functional outcomes associated with lack of
remission in schizophrenia: a post-hoc analysis of a prospective observational
study. BMC Psychiatry 12, 222.
Helldin, L., Kane, J.M., Karilampi, U., Norlander, T., Archer, T., 2007. Remission in prognosis
of functional outcome: a new dimension in the treatment of patients with psychotic
disorders. Schizophr. Res. 93 (1–3), 160–168.
Hong, J., Windmeijer, F., Novick, D., Haro, J.M., Brown, J., 2009. The cost of relapse in
patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health
Outcomes) study. Prog. Neuropsychopharmacol. Biol. Psychiatry 33 (5), 835–841.
Hough, D., Gopal, S., Vijapurkar, U., Lim, P., Morozova, M., Eerdekens, M., 2010.
Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in
patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
Schizophr. Res. 116 (2–3), 107–117.
Kane, J., Sanchez, R., Perry, P., Jin, N., Johnson, B., Forbes, R., McQuade, R., Carson, W.,
Fleischhacker, W., 2012. Aripiprazole intramuscular depot as maintenance treatment
in patients with schizophrenia: a 52-week multicenter, randomized, double-blind,
placebo-controlled study. J. Clin. Psychiatry 73 (5), 617–624.
Kane, J.M., Peters-Strickland, T., Baker, R.A., Hertel, P., Eramo, A., Jin, N., Perry, P.P., Gara,
M.A., McQuade, R.D., Carson, W.H., Sanchez, R., 2014. Aripiprazole once-monthly in
the acute treatment of schizophrenia: ﬁndings from a 12-week, randomized,
double-blind, placebo-controlled study. J. Clin. Psychiatry http://dx.doi.org/10.4088/
JCP.14m09168 [Epub ahead of print].
Karow, A., Moritz, S., Lambert, M., Schottle, D., Naber, D., Egofors Initiative, 2012. Remitted
but still impaired? Symptomatic versus functional remission in patients with schizo-
phrenia. Eur. Psychiatry 27 (6), 401–405.
Karve, S.J., Panish, J.M., Dirani, R.G., Candrilli, S.D., 2012. Health care utilization and costs
among medicaid-enrolled patients with schizophrenia experiencing multiple psychi-
atric relapses. Health Outcomes Res. Med. 3 (4), e183–e194.
Kasper, S., Lerman, M.N., McQuade, R.D., Saha, A., Carson, W.H., Ali, M., Archibald, D.,
Ingenito, G., Marcus, R., Pigott, T., 2003. Efﬁcacy and safety of aripiprazole vs. haloper-
idol for long-term maintenance treatment following acute relapse of schizophrenia.
Int. J. Neuropsychopharmacol. 6 (4), 325–337.
Kreyenbuhl, J., Buchanan, R.W., Dickerson, F.B., Dixon, L.B., Schizophrenia Patient Outcomes
Research Team, 2010. The Schizophrenia Patient Outcomes Research Team (PORT):
updated treatment recommendations 2009. Schizophr. Bull. 36 (1), 94–103.
Morosini, P.L., Magliano, L., Brambilla, L., Ugolini, S., Pioli, R., 2000. Development, reliability
and acceptability of a new version of the DSM-IV Social and Occupational Functioning
Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr. Scand.
101 (4), 323–329.
Pigott, T.A., Carson, W.H., Saha, A.R., Torbeyns, A.F., Stock, E.G., Ingenito, G.G., 2003.
Aripiprazole for the prevention of relapse in stabilized patients with chronic
schizophrenia: a placebo-controlled 26-week study. J. Clin. Psychiatry 64 (9), 1048–1056.
Rauch, A.S., Fleischhacker, W.W., 2013. Long-acting injectable formulations of new-
generation antipsychotics: a review from a clinical perspective. CNS Drugs 27 (8),
637–652.
Sliwa, J.K., Bossie, C.A., Ma, Y.W., Alphs, L., 2011. Effects of acute paliperidone palmitate
treatment in subjects with schizophrenia recently treated with oral risperidone.
Schizophr. Res. 132 (1), 28–34.
Tandon, R., Nasrallah, H.A., Keshavan, M.S., 2010. Schizophrenia, “just the facts” 5. Treat-
ment and prevention. Past, present, and future. Schizophr. Res. 122 (1–3), 1–23.
Wunderink, L., Nieboer, R.M., Wiersma, D., Sytema, S., Nienhuis, F.J., 2013. Recovery in
remitted ﬁrst-episode psychosis at 7 years of follow-up of an early dose reduction/
discontinuation or maintenance treatment strategy: long-term follow-up of a 2-
year randomized clinical trial. JAMA Psychiatry 70 (9), 913–920.
